Postbiotics as emerging therapeutic agents in inflammation-mediated metabolic disorders: Mechanisms, gut microbiota modulation, and clinical potential

Metabolic disorders such as obesity, type 2 diabetes mellitus (T2DM), and non-alcoholic fatty liver disease (NAFLD) are rapidly increasing global health concerns closely linked to chronic low-grade inflammation and gut microbiota dysbiosis. Recent advances in microbiome research have highlighted postbiotics—bioactive compounds derived from inactivated microorganisms and their metabolic by-products—as promising therapeutic agents for metabolic disease management. Postbiotics include short-chain fatty acids (SCFAs), microbial cell wall components, enzymes, vitamins, exopolysaccharides, and heat-killed bacterial cells, all of which exhibit immunomodulatory, antioxidant, anti-inflammatory, and metabolic regulatory activities. These compounds enhance intestinal barrier integrity, regulate immune signaling pathways such as TLR4/NF-κB and NLRP3 inflammasome, and improve metabolic homeostasis through modulation of glucose and lipid metabolism. SCFAs, particularly butyrate, acetate, and propionate, play a central role in restoring gut integrity, reducing endotoxemia, and promoting regulatory T-cell differentiation. Preclinical evidence suggests that postbiotics derived from genera such as Lactobacillus, Bifidobacterium, and Akkermansia muciniphila can significantly improve metabolic outcomes by reducing inflammation and enhancing gut–metabolic axis function. Despite promising findings, clinical translation remains limited, and further human studies are required to establish efficacy, safety, and standardized therapeutic protocols. This review provides a comprehensive overview of the classification, mechanisms of action, and therapeutic potential of postbiotics in inflammation-mediated metabolic disorders, highlighting their emerging role as next-generation microbiome-based interventions.

Authors

Publication Details

Journal
IP Journal of Nutrition Metabolism and Health Science
Published
2026-11-18
DOI
https://doi.org/10.18231/j.ijnmhs.28994.1794997868
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Postbiotics as emerging therapeutic agents in inflammation-mediated metabolic disorders: Mechanisms, gut microbiota modulation, and clinical potential

Rohit Ramesh Doke, MOHIT MITKARI, Yash Kanse, Isha Mandge et al.
2 links
IP Journal of Nutrition Metabolism and Health Science
Gut microbiota and health
article

Postbiotics as emerging therapeutic agents in inflammation-mediated metabolic disorders: Mechanisms, gut microbiota modulation, and clinical potential

Rohit Ramesh Doke, MOHIT MITKARI, Yash Kanse, Isha Mandge, Midhat Pathan
article en

Abstract

Metabolic disorders such as obesity, type 2 diabetes mellitus (T2DM), and non-alcoholic fatty liver disease (NAFLD) are rapidly increasing global health concerns closely linked to chronic low-grade inflammation and gut microbiota dysbiosis. Recent advances in microbiome research have highlighted postbiotics—bioactive compounds derived from inactivated microorganisms and their metabolic by-products—as promising therapeutic agents for metabolic disease management. Postbiotics include short-chain fatty acids (SCFAs), microbial cell wall components, enzymes, vitamins, exopolysaccharides, and heat-killed bacterial cells, all of which exhibit immunomodulatory, antioxidant, anti-inflammatory, and metabolic regulatory activities. These compounds enhance intestinal barrier integrity, regulate immune signaling pathways such as TLR4/NF-κB and NLRP3 inflammasome, and improve metabolic homeostasis through modulation of glucose and lipid metabolism. SCFAs, particularly butyrate, acetate, and propionate, play a central role in restoring gut integrity, reducing endotoxemia, and promoting regulatory T-cell differentiation. Preclinical evidence suggests that postbiotics derived from genera such as Lactobacillus, Bifidobacterium, and Akkermansia muciniphila can significantly improve metabolic outcomes by reducing inflammation and enhancing gut–metabolic axis function. Despite promising findings, clinical translation remains limited, and further human studies are required to establish efficacy, safety, and standardized therapeutic protocols. This review provides a comprehensive overview of the classification, mechanisms of action, and therapeutic potential of postbiotics in inflammation-mediated metabolic disorders, highlighting their emerging role as next-generation microbiome-based interventions.

IP Journal of Nutrition Metabolism and Health ScienceVol. 9(3)
Good health and well-being
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon